A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006876/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the efficacy and dose response of intranasal
esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with
placebo in improving depressive symptoms in participants with treatment-resistant depression
(TRD).
提供机构：
Vivli
创建时间：
2021-04-15
